Stockscreener 앱 받기
4.28
4.46%
-0.20
전일 마감가:
$4.48
열려 있는:
$4.42
하루 거래량:
146.97K
Relative Volume:
0.51
시가총액:
$157.02M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-2.51%
1개월 성능:
+5.42%
6개월 성능:
-29.61%
1년 성능:
+0.00%
1일 변동 폭
$4.28
$4.445
1주일 범위
$4.14
$4.57
52주 변동 폭
$2.88
$26.62
Bioage Labs Inc Stock (BIOA) Company Profile
명칭
Bioage Labs Inc
전화
510-806-1445
주소
1445A SOUTH 50TH STREET, RICHMOND
BIOA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
4.28 | 157.02M | 0 | 0 | 0 | 0.00 |
|
RGC
Regencell Bioscience Holdings Ltd
|
21.73 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
157.23 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.50 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.97 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.00 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-28 | 개시 | William Blair | Mkt Perform |
| 2024-12-10 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-12-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-10-21 | 개시 | Citigroup | Buy |
| 2024-10-21 | 개시 | Jefferies | Buy |
| 2024-10-21 | 개시 | Morgan Stanley | Overweight |
모두보기
Bioage Labs Inc 주식(BIOA)의 최신 뉴스
BioAge to analyze 17,000 HUNT Biobank samples for aging research By Investing.com - Investing.com Nigeria
BioAge Labs to Profile Norwegian Biobank for Aging Drug Discovery - MarketScreener
BioAge Labs expands drug discovery platform with data from HUNT Biobank - TipRanks
BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank - Yahoo Finance
BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review - marketscreener.com
Healthcare companies chase cures and capital in South Florida - Sun Sentinel
An Investigation Has Commenced on Behalf of BioAge Labs, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your BIOA Losses. - ACCESS Newswire
BioAge Labs Elects Directors at Annual Meeting - TipRanks
BIOA CLASS ACTION ALERT: BioAge Labs's 76% Stock Drop Triggers Securities Fraud Class Action; Contact BFA Law before March 10 Deadline - ACCESS Newswire
Lead Plaintiff Appointed in BioAge Labs Class Action — Here’s How You Can Recover Your Losses - TradingView
BioAge Labs, Inc. Announces Updates on APJ Agonist Program Updates - marketscreener.com
BioAge Labs Updates Milestones for NLRP3 Program - TipRanks
Bioage advances apelin receptor agonist program with option to Jikang’s nanobody - BioWorld MedTech
BioAge deepens weight loss R&D with fresh apelin receptor push - The Pharma Letter
BioAge Labs expands APJ agonist pipeline with biologic candidates - TipRanks
BioAge Labs Enters Option Agreement with JiKang Therapeutics to In-License Novel APJ Agonist Antibody and Expands Intellectual Property for Small Molecule APJ Agonists - Nasdaq
BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates - The Manila Times
Breakthrough Obesity Drug Pipeline: BioAge's New Treatment Doubles GLP-1 Weight Loss Effect - Stock Titan
Analysts Offer Insights on Healthcare Companies: Talkspace (TALK) and BioAge Labs, Inc. (BIOA) - The Globe and Mail
Bioage plans mid-year IND submission for BGE-102 for obesity - BioWorld MedTech
BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic - Pipelinereview
BioAge advances obesity drug into clinical trials By Investing.com - Investing.com South Africa
BioAge Labs, Inc. (BIOA)’s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025 - Insider Monkey
Jefferies maintains hold on BioAge Labs with $4 target By Investing.com - Investing.com India
Jefferies maintains hold on BioAge Labs with $4 target - Investing.com
BioAge Labs, Inc. Completes IND-enabling Studies for BGE-102 - marketscreener.com
BioAge advances obesity drug into clinical trials - Investing.com Australia
BioAge Labs completes IND-enabling studies for BGE-102, a - GlobeNewswire
BioAge Labs to Present at Upcoming Investor Conferences - The Manila Times
BioAge Labs Announces Major Investor Presentations: Key Updates Expected at Global Healthcare Conferences - Stock Titan
BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Class Action Filed Against BioAge Labs, Inc. (BIOA) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
BioAge Leaders Touted Obesity Drug Before Safety Woes, Suit Says - Bloomberg Law News
Invitation to presentation of BioArctic's first quarter report for JanuaryMarch 2025 on May 21 at 9.30 a.m. CET - Stock Titan
Investors who Lost Money on BioAge Labs, Inc. (BIOA) Should Contact Levi & Korsinsky About Pending Class ActionBIOA - ACCESS Newswire
Cautious Outlook on BioAge Labs, Inc. Amid Program Setbacks and Financial Concerns - TipRanks
Lost Money on BioAge Labs, Inc. (BIOA)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of BioAge Labs, Inc.(BIOA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of BioAge Labs, Inc. (BIOA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Levi & Korsinsky Notifies BioAge Labs, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineBIOA - ACCESS Newswire
Investors in BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights – BIOA - ACCESS Newswire
BioAge Labs, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsBIOA - ACCESS Newswire
Levi & Korsinsky Reminds BioAge Labs, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsBIOA - ACCESS Newswire
BioAge Labs Advances Pipeline with Strategic Collaborations - TipRanks
BioAge Labs, Inc Q1 Loss Narrows - Nasdaq
BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates - The Manila Times
With 44% stake, BioAge Labs, Inc. (NASDAQ:BIOA) seems to have captured institutional investors' interest - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
INVESTOR DEADLINE MONDAY: BioAge Labs, Inc. Investors with Subst - GuruFocus
Shareholder Rights Advocates at Levi & Korsinsky Investigate BioAge Labs, Inc. (BIOA) Regarding Possible Securities Fraud Violations - ACCESS Newswire
BioAge Labs, Inc. Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for Details- BIOA - ACCESS Newswire
Bioage Labs Inc (BIOA) 재무 분석
Bioage Labs Inc (BIOA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Bioage Labs Inc 주식 (BIOA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Pande Vijay Satyanand | Director |
Oct 01 '24 |
Buy |
19.73 |
126,793 |
2,501,626 |
1,026,793 |
| Pande Vijay Satyanand | Director |
Oct 02 '24 |
Buy |
19.73 |
67,096 |
1,323,804 |
1,093,889 |
| Pande Vijay Satyanand | Director |
Oct 03 '24 |
Buy |
19.90 |
25,306 |
503,589 |
1,119,195 |
| Cormorant Asset Management, LP | Former 10% Owner |
Sep 27 '24 |
Buy |
18.00 |
450,000 |
8,100,000 |
1,629,529 |
| Pande Vijay Satyanand | Director |
Sep 27 '24 |
Buy |
18.00 |
900,000 |
16,200,000 |
900,000 |
| ENRIGHT PATRICK G | Director |
Sep 27 '24 |
Buy |
18.00 |
400,000 |
7,200,000 |
1,710,589 |
| HEALY JAMES | Director |
Sep 27 '24 |
Buy |
18.00 |
666,665 |
11,999,970 |
2,227,124 |
1.85%
0.67%
자본화:
|
볼륨(24시간):